浙江帕瓦新能源股份有限公司 独立董事提名人声明与承诺 提名人浙江帕瓦新能源股份有限公司董事会，现提名蒋贤品为浙江帕瓦新能 源股份有限公司第四届董事会独立董事候选人，并已充分了解被提名人职业、学 历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等情况。被提 名人已书面同意出任浙江帕瓦新能源股份有限公司第四届董事会独立董事候选 人（参见该独立董事候选人声明）。提名人认为，被提名人具备独立董事任职资 格，与浙江帕瓦新能源股份有限公司之间不存在任何影响其独立性的关系，具体 声明并承诺如下： 二、被提名人任职资格符合下列法律、行政法规和部门规章的要求： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行政法规、 规章及其他规范性文件，具有五年以上法律、经济、会计、财务、管理等履行独 立董事职责所必需的工作经验。 （一）《中华人民共和国公司法》等关于董事任职资格的规定； 被提名人已经参加培训并取得证券交易所认可的相关培训证明材料。 （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及公司章程有关独立董事任职资格 ...

涉案的金额： 原告帕瓦供应链请求法院判令被告浙江格派钴业新材料有限公司返还预付 加工费人民币 1,300 万元及该款自 2025 年 7 月 31 日起至款付清之日止按 LPR 计算的利息损失。判令本案诉讼费由被告浙江格派钴业新材料有限公司承担。 是否会对上市公司损益产生负面影响：本次诉讼各方已达成和解，撤诉 裁定不会对公司的日常生产经营产生负面影响，也不会对公司当期及未来的损益 产生负面影响。 经过双方友好协商，浙江格派钴业新材料有限公司已返还帕瓦供应链预付加 工费 1,300 万元，双方就本次涉诉事项达成和解。2025 年 8 月 27 日帕瓦供应链 收到浙江省兰溪市人民法院（以下简称"法院"）出具的《民事裁定书》（〔2025〕 浙 0781 民初 5245 号之二）。根据上述裁定书，就原告帕瓦供应链与被告浙江格 派钴业新材料有限公司合同纠纷一案，法院裁定准许撤诉。现就有关情况公告如 下： 一、本次诉讼的基本情况 证券代码：688184 证券简称：ST 帕瓦 公告编号：2025-074 浙江帕瓦新能源股份有限公司 关于公司提起诉讼事项的进展公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性 ...

Core Points - The Sci-Tech Innovation 50 Index experienced a slight increase, closing at 1149.15 points with a gain of 0.09% and a trading volume of approximately 657.2 billion [1] - Most stocks on the Sci-Tech board declined, with 165 stocks rising; high-priced stocks showed mixed performance while low-priced stocks mostly fell [1] - In specific sectors, stocks related to environmental protection, healthcare, and biopharmaceuticals were active, whereas semiconductor, communication equipment, and electrical equipment stocks declined [1] Trading Performance - On August 21, the average decline for 589 stocks on the Sci-Tech board was 0.93%, with an average turnover rate of 3.82% and a total trading volume of 217.6 billion [1] - The average volatility for the stocks was 4.64% [1] Individual Stock Performance - Sanwei Xinan led the gainers with a 20% increase, while Dongxin Co. had the largest decline at 12.37% [2] - Cambrian's trading volume was the highest at 11.93 billion, while ST Pava had the lowest at 1.439 million [3] Turnover Rate - Yingshi Innovation had the highest turnover rate at 23.30%, while Bairen Medical had the lowest at 0.28% [4]

Core Viewpoint - Zhejiang Pava New Energy Co., Ltd. has initiated legal proceedings against Zhejiang Gepai Cobalt Industry New Materials Co., Ltd. and Zhejiang Lujia New Materials Co., Ltd. regarding contract disputes related to processing agreements and the return of goods [1][3][4]. Group 1: Lawsuit Details - The lawsuit has been accepted by the court but has not yet been heard [1][3]. - Zhejiang Pava New Energy Co., Ltd. is the plaintiff in the case against Zhejiang Gepai Cobalt Industry New Materials Co., Ltd., seeking the return of 230 tons of PW508 and 162 tons of PW302 goods, or compensation if the goods cannot be returned [1][7]. - The company is also seeking the return of a total of 1,228,379.66 kg of goods from Zhejiang Lujia New Materials Co., Ltd., with similar compensation terms if the goods cannot be returned [1][7]. Group 2: Financial Claims - Zhejiang Pava Supply Chain Management Co., Ltd., a wholly-owned subsidiary of Zhejiang Pava, is requesting the return of a prepaid processing fee of 13 million RMB from Zhejiang Gepai Cobalt Industry New Materials Co., Ltd., along with interest calculated based on the Loan Prime Rate (LPR) from July 31, 2025, until full payment is made [2][6][7]. - The total amount involved in the lawsuits includes the return of goods and the processing fee, highlighting significant financial stakes for the company [1][2][7]. Group 3: Impact on Operations - The company asserts that the lawsuits will not affect its normal production and operations, emphasizing that the legal actions are aimed at protecting its and its shareholders' rights [2][8]. - The actual impact on the company's profits remains uncertain until the court's decisions are made and executed [2][8].

证券代码：688184 证券简称：ST 帕瓦 公告编号：2025-073 浙江帕瓦新能源股份有限公司 关于公司提起诉讼事项的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、原告浙江帕瓦新能源股份有限公司（以下简称"公司"或"帕瓦股份"） 请求法院判令被告浙江格派钴业新材料有限公司返还 230 吨型号为 PW508 和 162 吨型号为 PW302 的货物，如被告不能返还上述货物的，判令被告浙江格派钴业新 材料有限公司折价赔偿； 2、原告帕瓦股份请求法院判令被告浙江路加新材料有限公司返还合计 1,228,379.66kg 的货物，如被告不能返还上述货物的，判令被告浙江路加新材 料有限公司折价赔偿。 3、原告浙江帕瓦供应链管理有限公司（公司全资子公司，以下简称"帕瓦 供应链"）请求法院判令被告浙江格派钴业新材料有限公司返还预付加工费人民 币 1,300 万元及该款自 2025 年 7 月 31 日起至款付清之日止按 LPR 计算的利息损 失。判令本案诉讼费由被告浙江格派钴业新材料有限公司承担。 是否会对 ...

证券代码：688184 证券简称：ST 帕瓦 公告编号：2025-072 ? 是否会对上市公司损益产生负面影响：浙江帕瓦新能源股份有限公司（以 下简称"公司"）本次诉讼不会影响公司正常生产经营。公司在本次诉讼案件中 为原告，鉴于本次诉讼尚未开庭审理，上述事项对公司当期及期后利润的影响具 有不确定性，最终实际影响以法院判决及实际执行结果为准。 一、本次诉讼的基本情况 公司于近日就公司与湖南恒优能科技有限公司货款纠纷事项向浙江省诸暨 市人民法院提起诉讼，并收到受理法院出具的《案件受理通知书》 （案号： 浙江帕瓦新能源股份有限公司 关于公司提起诉讼事项的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 案件所处的诉讼阶段：法院已立案受理，尚未开庭审理。 ? 公司所处的当事人地位：原告 ? 涉案的金额：原告请求法院判令被告向原告支付货款 39,403,975.10 元 及违约金、诉讼费、保全费等其他费用等。 （2025） 浙 0681 民初 16517 号）。截至本公告披露日，该案件尚未开庭审理。 二、诉讼案 ...

公司于近日就公司与湖南恒优能科技有限公司货款纠纷事项向浙江省诸暨 市人民法院提起诉讼，并收到受理法院出具的《案件受理通知书》（案号：（2025） 浙 0681 民初 16517 号）。截至本公告披露日，该案件尚未开庭审理。 二、诉讼案件基本情况 （一）诉讼当事人 证券代码：688184 证券简称：ST 帕瓦 公告编号：2025-072 浙江帕瓦新能源股份有限公司 关于公司提起诉讼事项的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 涉案的金额：原告请求法院判令被告向原告支付货款 39,403,975.10 元 及违约金、诉讼费、保全费等其他费用等。 是否会对上市公司损益产生负面影响：浙江帕瓦新能源股份有限公司（以 下简称"公司"）本次诉讼不会影响公司正常生产经营。公司在本次诉讼案件中 为原告，鉴于本次诉讼尚未开庭审理，上述事项对公司当期及期后利润的影响具 有不确定性，最终实际影响以法院判决及实际执行结果为准。 一、本次诉讼的基本情况 原告：浙江帕瓦新能源股份有限公司 统一社会信用代码：913306813 ...

Group 1 - The average premium of the latest closing prices of listed Sci-Tech Innovation Board stocks compared to their issue prices is 117.77%, with 144 stocks experiencing a decline in price [1][2] - Among the 589 listed Sci-Tech Innovation Board stocks, 444 stocks have a closing price higher than their issue price, while 144 stocks have fallen below their issue price [1][2] - The stock with the highest premium is Shuangwei New Materials, with a closing price that is 3676.98% higher than its issue price, followed by Hotgen Biotech and Baile Tianheng with premiums of 1163.70% and 1108.14% respectively [1][2] Group 2 - The stock with the largest decline is Wanrun New Energy, with a closing price that is 78.93% lower than its issue price, issued at 299.88 yuan [1][2] - ST Pava follows with a decline of 76.47%, issued at 51.88 yuan, and other notable declines include Chengda Bio at 71.31% and Tianyi New Materials at 65.75% [2][3] - The average price-to-earnings ratio for Wanrun New Energy is 75.25 times, significantly higher than the industry average of 19.21 times [1][2] Group 3 - The data shows a significant number of stocks experiencing price declines, with several stocks like Kangsino and Jindike also showing declines of over 50% [2][3] - The trend indicates a potential market correction for certain sectors within the Sci-Tech Innovation Board, particularly for companies with high initial valuations [1][2] - The overall performance of the Sci-Tech Innovation Board reflects a mixed sentiment among investors, with a substantial number of stocks still trading at a premium despite the presence of several underperformers [1][2]

Core Viewpoint - The article highlights a series of criminal investigations and penalties faced by various listed companies in China due to financial misconduct, including embezzlement, false financial reporting, and other violations of securities laws [2][3]. Group 1: ST Pava Case - ST Pava disclosed that its co-actual controller and director, Zhang Bao, is under criminal investigation for embezzlement, with a total of 191.34 million yuan misappropriated, of which only 30 million yuan has been returned as of July 26, 2025 [2]. - This incident marks ST Pava as the eighth listed company since July to have executives or actual controllers involved in criminal activities related to financial misconduct [3]. Group 2: Hongxiang Shares Case - Hongxiang Shares' actual controller, Yang Cheng, is under criminal investigation for financial misconduct, with previous penalties from the China Securities Regulatory Commission for false financial reporting from 2017 to 2022, including inflated revenues and profits [4][5]. - The company reported inflated revenues of 104.89 million yuan in 2017, 255.59 million yuan in 2018, and other significant amounts in subsequent years, leading to severe penalties [5][6]. Group 3: Liyuan Technology Case - Liyuan Technology's actual controller, Shen Wanzhong, received a criminal sentence for violating information disclosure laws, with inflated revenues reported in 2021 amounting to over 103.84 million yuan, constituting 24.71% of the disclosed revenue [6][7]. Group 4: Jintongling Case - Jintongling is facing criminal charges for providing false financial data over six consecutive years, with significant misreporting of losses as profits, leading to severe investor losses [8]. Group 5: ST Qibu Case - ST Qibu is under investigation for financial fraud, with allegations of profit inflation and false disclosures in bond issuance documents, leading to criminal charges against responsible personnel [9][10]. Group 6: ST Dongshi Case - ST Dongshi's actual controller, Xu Xiong, was sentenced for market manipulation, receiving a six-and-a-half-year prison term and a fine of 170 million yuan [11]. Group 7: Ruiskanda Case - Ruiskanda's executives are facing criminal charges for misleading disclosures, with inflated revenues reported in 2019 and 2020 amounting to 35.13 million yuan and 28.13 million yuan, respectively [12]. Group 8: Tuidi Jinguang Case - Tuidi Jinguang's executives were arrested for significant financial misreporting, with inflated profits reported in 2022, 2023, and 2024, amounting to 36.10 million yuan, 68.09 million yuan, and 15.38 million yuan, respectively [13][14].

Core Viewpoint - ST Pava (688184.SH) is facing significant challenges due to the investigation of its former chairman Zhang Bao for embezzlement, alongside ongoing financial difficulties and declining performance since its IPO in 2022 [1][2][6]. Financial Performance - In 2023, ST Pava reported a revenue of 9.54 billion, a decrease of 42.38% year-on-year, and a net loss of 2.48 billion, marking a shift from profit to loss [6][8]. - For 2024, the company achieved a revenue of 9.49 billion, a slight decline of 0.6%, with a net loss of 7.27 billion, indicating a worsening financial situation [6][8]. - Cumulatively, the company has incurred losses of 9.75 billion over two consecutive years [6]. Product and Market Dynamics - The company's main product, lithium-ion battery ternary precursor materials, has seen a significant drop in average selling prices, leading to increased inventory impairment and reduced gross margins [6][7]. - In 2024, the sales volume of ternary precursors reached 16,883.5 tons, a year-on-year increase of 37.94%, but the average selling price fell by 24.05% to 55,400 per ton [7][8]. - The gross margin for the company's core products turned negative, with gross margins for single crystal and multi-crystal NCM ternary precursors at -18.81% and -48.35%, respectively [8]. Management Changes - Following the investigation, Zhang Bao resigned as chairman and was succeeded by Wang Baoliang, who previously held the position from 2016 to 2022 [5][9]. - The effectiveness of Wang Baoliang's leadership in reversing the company's fortunes remains uncertain [9]. Regulatory and Audit Issues - The company has faced multiple regulatory warnings, including a negative audit opinion regarding its internal controls and financial reporting [2][5]. - ST Pava's stock was reclassified to "ST Pava" due to risk warnings, reflecting the ongoing financial and operational challenges [2].